Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sanofi’s recent clinical study, officially titled ‘A Phase 1/2, Dose Escalation, Dose Expansion, and Dose Optimization Study of the Safety, Tolerability, and Anti-tumor Activity of SAR444881 Administered Alone and in Combination With Pembrolizumab, Cetuximab and/or Chemotherapy in Participants With Advanced Solid Tumors,’ aimed to evaluate the safety and anti-tumor activity of SAR444881 in patients with advanced solid tumors. This study is significant as it explores new treatment combinations for patients who are not candidates for standard therapies.
The intervention being tested is SAR444881, a drug administered intravenously, both alone and in combination with other therapeutics like pembrolizumab, cetuximab, carboplatin, and pemetrexed. The goal is to determine the optimal dose and assess the drug’s efficacy in treating various advanced cancers.
The study was designed as a non-randomized, sequential intervention model focusing on treatment. It included a dose escalation phase and a dose optimization/expansion phase, with no masking involved. The primary purpose was to explore treatment efficacy and safety.
The study began on April 11, 2021, and was last updated on August 4, 2025. However, it has been terminated, which could impact the timeline for any potential market release of SAR444881.
The termination of this study might influence Sanofi’s stock performance and investor sentiment, as it could delay the introduction of new cancer treatments. Competitors in the oncology space may gain an advantage if they have ongoing successful trials.
The study has been terminated, but further details can be accessed on the ClinicalTrials portal.